Director, Chief Executive Officer · Candel Therapeutics, Inc. · Common Stock
Side
SELL
Value
$621K
Shares
59.4K
Price
$10.46
Executed
Sep 11, 2026
Disclosed
Sep 11, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Sep 11 executedSep 11, 2026 disclosed
CADL · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Tak Paul Peter filed this Form 4 reporting a open-market sale of CADL on Sep 11, 2026. It became public on Sep 11, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, Chief Executive Officer
Tak Paul Petercik:0001873905
Issuer
Candel Therapeutics, Inc.cik:0001841387
Revision history · 0
No field has changed since this record was first ingested.
